Venetoclax plus leukemia drugs for AML after treatment failure
Treatments studied
Part of Blood & lymphatic, Cancer clinical trials.
This Phase 1 trial studies whether a combination of venetoclax (ABT-199) and “purine analogues” can help adults with AML that has come back or didn’t respond to earlier treatment. It’s designed to test safety and early effectiveness in people who haven’t previously developed resistance to venetoclax.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have acute myeloid leukemia (AML) that has relapsed or not responded to treatment
- Your AML has either come back after intensive chemotherapy or hasn’t responded to it, or it didn’t respond after 4 cycles of a drug class called HMAs
- You’re 18 years or older
- You can do most normal activities or self-care (performance status 0–2)
- You have not used venetoclax before, or if you did, you were not “venetoclax-refractory” (not resistant) and your study doctor agrees
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 1 trial tests whether venetoclax, combined with chemotherapy and a “cancer cell behavior” medicine strategy, can improve treatment for people with AML that has come back or not gone into remission. It’s mainly looking at safety and early signs of benefit.
This trial studies how well venetoclax combined with chemotherapy treats newly diagnosed or returning (relapsed) or hard-to-treat (refractory) acute myeloid leukemia (AML). It’s mainly for people who can’t use standard AML therapy well, or whose disease came back.
This trial tests a combination of venetoclax with liposome chemotherapy (daunorubicin and cytarabine) for adults with acute myeloid leukemia (AML) that is back after treatment or not responding, and for some newly diagnosed cases. It aims to shrink leukemia and help more people achieve remission.
This study tests a combination of two drugs (MDCyta and venetoclax) after an initial treatment to see if it helps people with newly diagnosed AML stay in remission. It is for adults aged 18 to 60 who are otherwise fairly healthy.
This early-phase study tests whether venetoclax combined with intensive chemotherapy can treat AML (acute leukemia) and certain advanced MDS. It’s for people who are newly diagnosed (or certain high-risk blood cancers) and can safely tolerate strong treatment.
This trial studies venetoclax combined with CLAG-M chemotherapy to treat adults with high-risk acute myeloid leukemia (AML) or related high-grade blood cancers. It aims to improve control of the disease, especially in people whose AML is considered high risk.
Hear when a new Acute Myeloid Leukemia, in Relapse trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.